Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994138 | 0.85 | MAPT (0.49) | ALDH1A1KDM4E | |
| SCHEMBL4681966 | 0.84 | MAPT (0.38) | ALDH1A1 | |
| SCHEMBL3028596 | 0.81 | NOTUM (0.45) | LRRK2ALKPIM1ALDH1A1CYP1A2 | |
| SCHEMBL3032907 | 0.79 | NOTUM (0.43) | ALDH1A1BRD4ADORA3 | |
| SCHEMBL2821218 | 0.79 | CACNA1F (0.41) | ALDH1A1POLBKDM4E | |
| SCHEMBL3033106 | 0.79 | PTGS1 (0.50) | ALDH1A1BRD4ADORA3 | |
| SCHEMBL3033408 | 0.77 | PTGS2 (0.42) | ALPLALDH1A1BRD4KDM4E | |
| SCHEMBL3029374 | 0.77 | GAA (0.48) | ALDH1A1 | |
| SCHEMBL4708510 | 0.75 | ROCK1 (0.36) | ALDH1A1 | |
| SCHEMBL3027304 | 0.75 | KIT (0.38) | ALDH1A1BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2010-08-12 | — | — | US | disclosed |
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2009-04-30 | — | — | US | disclosed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | disclosed |
| EP-1575926-B1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL LAB (ES) | 2008-03-05 | — | — | EP | disclosed |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-03 | — | — | US | disclosed |
| EP-1575926-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058729-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | MAP2K4 1966/4885IDO1 715/4885LRRK2 2648/4885 |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | PDE3A, PDE4A, PDE3B | MAP2K4 2112/4885IDO1 798/4885LRRK2 2939/4885 |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | MAP2K4 1966/4885IDO1 715/4885LRRK2 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.